TMS was founded in 2005 to commercialize discoveries centering coagulation and fibrinolysis system by scientists at Tokyo University of Agriculture and Technology, including Dr. Keiji Hasumi. Earlier research activities were participated by Dr. Akira Endo (inventor of cholesterol lowering drug statin, winner of Lasker-DeBakey Clinical Medical Research Award in 2008 and Gairdner International Award 2017) who was a professor of the university until 1997.
SMTP, a family of small molecule compounds having both thrombolytic and anti-inflammatory effect, was identified through the research activites.
In June 2018, TMS signed an option agreement to assign TMS-007, its lead program indicating acute ischemic stroke, and related assets to Biogen for a total of $ 357 million milestone payment, which is the largest deal ever entered into by a Japanese biotech company.
|
Feb. 2005 |
TMS Co., Ltd. founded |
|---|
|
2005 - 2011 |
Demonstrated thrombolytic and anti-inflammatory activities of SMTP ameliorate ischemic stroke in pharmacological studies of SMTP |
|---|
|
Nov. 2011 |
Started IND-enabling study of TMS-007 |
|---|
|
Oct. 2014 |
Started Phase I clinical trial of TMS-007 |
|---|
|
Oct. 2015 |
Completed Phase I clinical trial of TMS-007 |
|---|
|
Feb. 2018 |
Started phase IIa clinical trial of TMS-007 for ischemic stroke patients |
|---|
|
Jun. 2018 |
Option agreement with Biogen on TMS-007 |
|---|
|
May. 2021 |
Biogen exercised an option to acquire TMS-007 |
|---|
|
Aug. 2021 |
Completed phase IIa clinical trial of TMS-007 |
|---|
|
Nov. 2022 |
Listing on the Tokyo Stock Exchange Growth Market(Securities code:4891) |
|---|
